Author

Yesim Dargaud

Professeur de m

Biography

Yesim Dargaud is a Professor in the Clinical Hemostasis Unit and Hemophilia Comprehensive Care Centre at Lyon University Hospitals, France. She is a member of the French Reference Centre for Hemophilia and Other Inherited Rare Bleeding Disorders. Yesim Dargaud's research interests focus on inherited bleeding disorders, novel therapeutic approaches of hemophilia with inhibitors, molecular and cellular biology of factor IX. She has a particular interest in the current and future approaches for personalized management of patients with haemophilia.
Title
Cited by
Year
Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis
C Nougier, R Benoit, M Simon, H Desmurs‐Clavel, G Marcotte, L Argaud, ...Journal of Thrombosis and Haemostasis 18 (9), 2215-2219, 2020202
232
2020
Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis
BK Tan, S Mainbourg, A Friggeri, L Bertoletti, M Douplat, Y Dargaud, ...Thorax 76 (10), 970-979, 2021202
228
2021
Increased blood viscosity and red blood cell aggregation in patients with COVID‐19
E Nader, C Nougier, C Boisson, S Poutrel, J Catella, F Martin, J Charvet, ...American journal of hematology 97 (3), 283-292, 2022202
42
2022
Direct oral anticoagulants for the treatment of cerebral venous thrombosis
A Lurkin, L Derex, A Fambrini, L Bertoletti, M Epinat, P Mismetti, ...Cerebrovascular Diseases 48 (1-2), 32-37, 2019201
31
2019
Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
M Ninivaggi, R de Laat‐Kremers, A Tripodi, D Wahl, S Zuily, Y Dargaud, ...Journal of Thrombosis and Haemostasis 19 (5), 1372-1378, 2021202
24
2021
Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic
X Delavenne, Y DargaudThrombosis Research 192, 52-60, 2020202
18
2020
A new paradigm for personalized prophylaxis for patients with severe haemophilia A
X Delavenne, E Ollier, A Lienhart, Y DargaudHaemophilia 26 (2), 228-235, 2020202
17
2020
Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A
X Delavenne, Y Dargaud, E Ollier, C NégrierBritish Journal of Clinical Pharmacology 85 (4), 771-781, 20120
9
2019
Impact of deficiency of intrinsic coagulation factors XI and XII on ex vivo thrombus formation and clot lysis
JWP Govers-Riemslag, J Konings, JMEM Cosemans, JP van Geffen, ...TH Open 3 (03), e273-e285, 20120
9
2019
Recombinant adeno-associated viral vectors expressing human coagulation FIX-E456H variant in hemophilia B mice
S Le Quellec, AP Dane, E Barbon, JC Bordet, F Mingozzi, Y Dargaud, ...Thrombosis and Haemostasis 119 (12), 1956-1967, 2019201
8
2019
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Y Dargaud, C Escuriola‐EttingshausenResearch and Practice in Thrombosis and Haemostasis 5 (8), e12631, 2021202
7
2021
Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
L Giffard-Quillon, H Desmurs-Clavel, C Grange, Y Jourdy, Y DargaudThrombosis Journal 18 (1), 1-5, 2020202
7
2020
Pregnancy and thrombosis: Adrenal vein thrombosis. A retrospective descriptive study of 14 cases
P Descargues, C Battie, C Huissoud, N Hoen, Y Dargaud, M Doret, ...European Journal of Obstetrics & Gynecology and Reproductive Biology 233, 38-42, 2019201
5
2019
Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study
M Janbain, N Enjolras, JC Bordet, R Bolbos, M Brevet, C Leissinger, ...Journal of Thrombosis and Haemostasis 18 (3), 84-92, 2020202
5
2020
Response to “Studies on hemostasis in COVID‐19 deserve careful reporting of the laboratory methods, their significance and their limitation”: Don’t throw the baby out with the …
C Nougier, R Benoit, Y DargaudJournal of Thrombosis and Haemostasis 18 (11), 3128-3130, 2020202
4
2020
Clinical utility of subcutaneous factor VIII replacement therapies in hemophilia A: a review of the evidence
Y Dargaud, M JanbainJournal of Blood Medicine, 1031-1036, 2021202
4
2021
The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic …
Y Dargaud, M Fouassier, JC Bordet, S Ducastelle-Lepretre, C Dumontet, ...Leukemia & lymphoma, 2019201
4
2019
The modification of the thrombin generation assay for the clinical assessment of hypercoagulability in patients receiving heparin therapy
R Benoit, C Nougier, H Desmurs‐Clavel, M Simon, Y DargaudInternational Journal of Laboratory Hematology (2), 371-378, 2022202
4
2022
Diagnostic biologique du syndrome des antiphospholipides
S Désage, Y DargaudRevue Francophone des Laboratoires 2020 (520), 4-41, 2020202
3
2020
Pregnancy-related thrombosis risk in patients with protein C deficiency and comparison with pregnant women with heterozygous factor V Leiden mutation
L Rugeri, S Desage, L Khouatra, C Battie, M Doret-Dion, C Trzeciak, ...Blood Coagulation & Fibrinolysis 1 (1), 55-59, 2020202
3
2020

Referred From: https://scholar.google.com.sg/citations?hl=en&user=NUChd9cAAAAJ

Cited by
Citations 4628
h-index 34
i10-index 67
Recommended Journals
Open Access Journals